Skip to content
Wednesday, March 29, 2023
Latest:
  • SQI Diagnostics Submits RALI-Dx(TM) IL-6 Severity Triage Test for COVID-19 Patients to FDA for Emergency Use Authorization
  • Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors
  • Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
  • PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin
  • MindMed Announces Inclusion in FTSE Russell Indexes
Biotech Stock Market News

Biotech Stock Market News

Know First, Act First

  • Cannabis & Cancer
  • General
  • Coronavirus
  • Financing & Fiscal
  • Shareholders

vaccine

BIOTCHNO Coronavirus 

The Top 3 Companies Racing to Create COVID-19 Vaccine

May 5, 2020May 24, 2021 Desiree Justice BioNTech, BNTX, coronavirus, COVID-19, GILD, Gilead Sciences, National Institute of Allergy and Infectious Diseases, PFE, vaccine

The coronavirus is still wreaking havoc around the world. To date, total confirmed global cases are up to 3.6 million,

Read more

Cannabis

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
BIOTCHNO Cannabis & Cancer 

Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan

March 31, 2021July 19, 2021 Raza

TOKYO, Mar 31, 2021 – (JCN Newswire) – Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co.,

The Valens Company Expands Cannabis 2.0 & 3.0
BIOTCHNO Cannabis & Cancer 

The Valens Company Expands Cannabis 2.0 & 3.0

February 25, 2021April 20, 2021 Bachittar
PAOG Announces CBD Nutraceuticals Expansion Plan Multimedia Presentation
BIOTCHNO Cannabis & Cancer 

PAOG Announces CBD Nutraceuticals Expansion Plan Multimedia Presentation

February 16, 2021April 30, 2021 Bachittar
ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
BIOTCHNO Cannabis & Cancer 

ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

February 11, 2021April 30, 2021 Bachittar
  • Disclaimer
  • Privacy Policy
TD Media LLC dba Life Water Media
5826 New Territory Blvd. Unit #2144 Sugar Land, TX 77479